Study of Tezepelumab Monthly Injection to Treat Severe Asthma in Adults Visiting Emergency Rooms with Asthma Attacks

What this Trial Is About

This trial evaluates Tezepelumab, a newly approved medication for adults with severe asthma who experience sudden worsening symptoms that require emergency care. The study aims to determine if starting Tezepelumab in the Emergency Department can help control asthma symptoms and reduce repeated visits or the need for steroid treatments. Adults with a history of asthma and recent exacerbations are the focus, and the trial compares Tezepelumab to a placebo in a phase 4 randomized, double-blinded study. Participants are randomized to receive either Tezepelumab 210 mg or a matching placebo through subcutaneous injections every four weeks for 90 days. After this period, all participants enter an open-label extension where they receive Tezepelumab for an additional 90 days. The study tracks the proportion of patients returning to the Emergency Department for asthma exacerbations during the first 90 days and again by day 180, while also monitoring other asthma control measures and drug safety. During the study, participants undergo regular assessments including asthma control questionnaires, lung function tests, and blood tests to measure inflammatory markers. The primary outcome is the rate of moderate and severe asthma exacerbations by day 90. Safety and tolerability of the medication are monitored throughout, and participants are followed for a total of 180 days. This research is sponsored by the University of Alberta and aims to provide important data on managing severe asthma in emergency settings.

Tezepelumab in the Treatment of Emergency Room Asthma in Adults (TERAA)